Healthy Returns: Sales of Humira are plunging, but AbbVie has two promising successors [CNBC]
Novartis AG (NVS)
Last novartis ag earnings: 4/28 01:00 am
Check Earnings Report
US:NYSE Investor Relations:
novartis.com/investors
Company Research
Source: CNBC
Sales of AbbVie 's Humira are plummeting as the once-top-selling drug fights competition from cheaper biosimilars in the U.S. and abroad. But AbbVie has two key drugs that treat many of the same conditions as Humira, and they are proving to be worthy successors to the company's flagship medication. That was clear after AbbVie on Friday reported first-quarter revenue and adjusted profit that topped Wall Street's expectations, partly driven by strength in the drugmaker's immunology business. The pharmaceutical giant also hiked its annual profit forecast. Humira revenue plunged more than 30% to $2.3 billion during the first quarter, according to AbbVie. For years, AbbVie has built up a wall of patent protections around the drug, effectively extending its market exclusivity well beyond its main U.S. patent expiration in 2016. But Humira lost exclusivity in the U.S. last year amid the launch of nine biosimilars, some of which have been available in Europe since 2019. A tenth biosim
Show less
Read more
Impact Snapshot
Event Time:
NVS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVS alerts
High impacting Novartis AG news events
Weekly update
A roundup of the hottest topics
NVS
News
- Oncodesign Precision Medicine and Navigo Proteins GmbH Sign a Strategic Collaboration Agreement for the Research and Development of New Systemic Radiotherapy Agents [Yahoo! Finance]Yahoo! Finance
- Novartis highlights pioneering innovation in CML with data from Scemblix® Phase III ASC4FIRST study in newly diagnosed patients at ASCO and EHA [Yahoo! Finance]Yahoo! Finance
- LEM Holding And Two More High-Yield Dividend Stocks To Consider [Yahoo! Finance]Yahoo! Finance
- The National Kidney Foundation's 2024 Spring Clinical Meetings Late-Breaking Presentation on New Therapy Shows Promising Results for IgAN Patients [Yahoo! Finance]Yahoo! Finance
- Global Oncolytic Virotherapy Market Research 2024: Industry Size, Share, Trends, Opportunity & Forecasts, 2019-2029 - Focus on Personalized Medicine, Clinical Advancements Spurs Growth [Yahoo! Finance]Yahoo! Finance
NVS
Earnings
- 4/23/24 - Beat
NVS
Sec Filings
- 4/23/24 - Form 6-K
- 2/15/24 - Form S-8
- NVS's page on the SEC website